Related News
Home » Business » Manufacturing
Sanofi's offer for Genzyme unchanged
By Nina Sovich |
September 28, 2010, Tuesday
|
Print Edition
Print Edition
SANOFI-AVENTIS has not changed its offer of US$69 per share for drug maker Genzyme, a Sanofi spokesman said yesterday, declining to comment on a report that it had lined up more financing for its bid.
"We have one offer at $69. No other offer has been made ... We would like to enter into a dialogue," said Sanofi spokesman Jean-Marc Podvin. He declined to comment on a Wall Street Journal report released over the weekend that said Sanofi-Aventis had lined up more financing from Citigroup and Bank of America Corp. Sanofi has said it already has financing from J.P. Morgan Chase & Co, BNP Paribas SA and Societe Generale SA.
The French drug maker wants to reach a friendly agreement but has not ruled out a hostile offer made directly to Genzyme shareholders, sources previously told Reuters. Last month, Genzyme rejected Sanofi's offer as dramatically undervaluing the company.
"We have one offer at $69. No other offer has been made ... We would like to enter into a dialogue," said Sanofi spokesman Jean-Marc Podvin. He declined to comment on a Wall Street Journal report released over the weekend that said Sanofi-Aventis had lined up more financing from Citigroup and Bank of America Corp. Sanofi has said it already has financing from J.P. Morgan Chase & Co, BNP Paribas SA and Societe Generale SA.
The French drug maker wants to reach a friendly agreement but has not ruled out a hostile offer made directly to Genzyme shareholders, sources previously told Reuters. Last month, Genzyme rejected Sanofi's offer as dramatically undervaluing the company.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
